Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Composition for Treating Cirrhosis and Liver Cancer
NCT05178303Phase 4Completed
- Start
- Nov 2015
- Primary completion
- Oct 2021
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 2
01
Overview
Phase 4 trial of SB-1121 in Cirrhosis and hepatocellular carcinoma (HCC) (2 arms). Primary endpoint: Stiffness of liver tissue measured by sound waves at 36 months. Started Nov 2015; status: completed.
02
Drugs
SB-1121
03
Conditions
Cirrhosishepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05178303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05178303.